Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic liver disease and type 2 diabetes. - Colletta A; Cooper KM; Placentino G; Devuni D; Colletta C (Frontiers in endocrinology, 2025)